Standard

КОМБИНИРОВАННАЯ ГЕПАТОПРОТЕКТОРНАЯ ФАРМАКОТЕРАПИЯ ЗАБОЛЕВАНИЙ ПЕЧЕНИ. / Оковитый, Сергей Владимирович; Райхельсон, Карина Леонидовна; Приходько, Вероника Александровна.

In: Экспериментальная и клиническая гастроэнтерология, Vol. 203, No. 7, 07.10.2022, p. 5-20.

Research output: Contribution to journal › Article › peer-review

Harvard

Оковитый, СВ, Райхельсон, КЛ & Приходько, ВА 2022, 'КОМБИНИРОВАННАЯ ГЕПАТОПРОТЕКТОРНАЯ ФАРМАКОТЕРАПИЯ ЗАБОЛЕВАНИЙ ПЕЧЕНИ', Экспериментальная и клиническая гастроэнтерология, vol. 203, no. 7, pp. 5-20. https://doi.org/10.31146/1682-8658-ecg-203-7-5-20

APA

Оковитый, С. В., Райхельсон, К. Л., & Приходько, В. А. (2022). КОМБИНИРОВАННАЯ ГЕПАТОПРОТЕКТОРНАЯ ФАРМАКОТЕРАПИЯ ЗАБОЛЕВАНИЙ ПЕЧЕНИ. Экспериментальная и клиническая гастроэнтерология, 203(7), 5-20. https://doi.org/10.31146/1682-8658-ecg-203-7-5-20

Vancouver

Оковитый СВ, Райхельсон КЛ, Приходько ВА. КОМБИНИРОВАННАЯ ГЕПАТОПРОТЕКТОРНАЯ ФАРМАКОТЕРАПИЯ ЗАБОЛЕВАНИЙ ПЕЧЕНИ. Экспериментальная и клиническая гастроэнтерология. 2022 Oct 7;203(7):5-20. https://doi.org/10.31146/1682-8658-ecg-203-7-5-20

Author

Оковитый, Сергей Владимирович ; Райхельсон, Карина Леонидовна ; Приходько, Вероника Александровна. / КОМБИНИРОВАННАЯ ГЕПАТОПРОТЕКТОРНАЯ ФАРМАКОТЕРАПИЯ ЗАБОЛЕВАНИЙ ПЕЧЕНИ. In: Экспериментальная и клиническая гастроэнтерология. 2022 ; Vol. 203, No. 7. pp. 5-20.

BibTeX

@article{4d3b24190c1141e3baee46d3e503703d,
title = "КОМБИНИРОВАННАЯ ГЕПАТОПРОТЕКТОРНАЯ ФАРМАКОТЕРАПИЯ ЗАБОЛЕВАНИЙ ПЕЧЕНИ",
abstract = "Fixed-dose drug products as well as non-fixed hepatoprotective drug combinations are commonly used in modern clinical practice. Combined and concurrent drug use makes it possible to augment the pharmacological effects of individual agents, or extend the range of their potential indications. The drugs most commonly considered for combination therapy include essential phospholipids, glycyrrhizinic acid, ursodeoxycholic acid, silibinin, and S-adenosylmethionine. This paper discusses the rationale for combined use of liver-targeting drugs from a pathogenetic viewpoint, and provides a review of the evidence from clinical trials on combined pharmacotherapy for liver disease.",
keywords = "S-adenosylmethionine, essential phospholipids, glycyrrhizinic acid, hepatoprotective agents, liver disease, silibinin, ursodeoxycholic acid",
author = "Оковитый, {Сергей Владимирович} and Райхельсон, {Карина Леонидовна} and Приходько, {Вероника Александровна}",
year = "2022",
month = oct,
day = "7",
doi = "10.31146/1682-8658-ecg-203-7-5-20",
language = "русский",
volume = "203",
pages = "5--20",
journal = "Экспериментальная и клиническая гастроэнтерология",
issn = "1682-8658",
publisher = "Глобал медиа технологии",
number = "7",

}

RIS

TY - JOUR

T1 - КОМБИНИРОВАННАЯ ГЕПАТОПРОТЕКТОРНАЯ ФАРМАКОТЕРАПИЯ ЗАБОЛЕВАНИЙ ПЕЧЕНИ

AU - Оковитый, Сергей Владимирович

AU - Райхельсон, Карина Леонидовна

AU - Приходько, Вероника Александровна

PY - 2022/10/7

Y1 - 2022/10/7

N2 - Fixed-dose drug products as well as non-fixed hepatoprotective drug combinations are commonly used in modern clinical practice. Combined and concurrent drug use makes it possible to augment the pharmacological effects of individual agents, or extend the range of their potential indications. The drugs most commonly considered for combination therapy include essential phospholipids, glycyrrhizinic acid, ursodeoxycholic acid, silibinin, and S-adenosylmethionine. This paper discusses the rationale for combined use of liver-targeting drugs from a pathogenetic viewpoint, and provides a review of the evidence from clinical trials on combined pharmacotherapy for liver disease.

AB - Fixed-dose drug products as well as non-fixed hepatoprotective drug combinations are commonly used in modern clinical practice. Combined and concurrent drug use makes it possible to augment the pharmacological effects of individual agents, or extend the range of their potential indications. The drugs most commonly considered for combination therapy include essential phospholipids, glycyrrhizinic acid, ursodeoxycholic acid, silibinin, and S-adenosylmethionine. This paper discusses the rationale for combined use of liver-targeting drugs from a pathogenetic viewpoint, and provides a review of the evidence from clinical trials on combined pharmacotherapy for liver disease.

KW - S-adenosylmethionine

KW - essential phospholipids

KW - glycyrrhizinic acid

KW - hepatoprotective agents

KW - liver disease

KW - silibinin

KW - ursodeoxycholic acid

UR - https://www.mendeley.com/catalogue/2193f7e3-5558-3a95-bda0-9f720243164e/

UR - http://www.scopus.com/inward/record.url?scp=85143404213&partnerID=8YFLogxK

U2 - 10.31146/1682-8658-ecg-203-7-5-20

DO - 10.31146/1682-8658-ecg-203-7-5-20

M3 - статья

VL - 203

SP - 5

EP - 20

JO - Экспериментальная и клиническая гастроэнтерология

JF - Экспериментальная и клиническая гастроэнтерология

SN - 1682-8658

IS - 7

ER -

ID: 99493411